{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-060693","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-14T11:20:27+00:00","discovered_at":"2026-05-14T11:25:00.337964+00:00","generated_at":"2026-05-14T11:26:28.518387+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cellectar reports Q1 net loss $5.7M; positive iopofosine data, up to $140M financing","bullets":["Q1 net loss $5.7M ($1.33/share) vs $6.6M ($4.30/share) YoY; cash $8.3M at March 31.","Positive 12-month follow-up from CLOVER WaM: 61.8% MRR, 83.6% ORR, median PFS 13.5 months in r/r WM.","Completed $35M upfront + up to $105M milestone financing led by Nantahala Capital; Andrew Gu to join board.","Initiated Phase 1b trial of CLR 125 in triple negative breast cancer; first patient dosed. Dosimetry data expected mid-2026.","Selected for ASCO 2026 presentation of CLOVER-WaM subgroup data on iopofosine post-BTKi therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-060693","json":"https://secwatch.observer/filing/0001104659-26-060693.json","markdown":"https://secwatch.observer/filing/0001104659-26-060693.md","text":"https://secwatch.observer/filing/0001104659-26-060693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/0001104659-26-060693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/tm2614602d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T11:26:28.518387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7c3eea3f65d76ec3cd602c750b818ec055e514b","claim":"Cellectar Biosciences, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/0001104659-26-060693-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}